Table 1.
Baseline characteristics of the cohort
| Characteristic | N | % |
|---|---|---|
| Age, median (range) | 67 (27–90) years | |
| Sex | ||
| Male | 84 | 42% |
| Female | 116 | 58% |
| Race | ||
| White | 43 | 22% |
| African American | 64 | 32% |
| Hispanic | 78 | 39% |
| Asian | 10 | 5% |
| Other | 5 | 3% |
| Type of malignancy | ||
| Solid tumor | 134 | 67% |
| Hematologic malignancy | 66 | 33% |
| Malignancy category | ||
| Solid tumor | ||
| Breast | 51 | 26% |
| Gastrointestinal | 27 | 14% |
| Genitourinary | 18 | 9% |
| Gynecologic oncology | 10 | 5% |
| Thoracic/head & neck | 25 | 13% |
| Skin/musculoskeletal | 2 | 1% |
| Carcinoma of unknown primary | 1 | 1% |
| Hematologic malignancy | ||
| Lymphoid | 26 | 13% |
| Myeloid | 18 | 9% |
| Plasma cell | 22 | 11% |
| Cancer status at the time of vaccine | ||
| Active | 110 | 55% |
| Progressive | 7 | 4% |
| Relapse/recurrent | 33 | 17% |
| Remission | 50 | 25% |
| Type of vaccine | ||
| BNT162b2 | 115 | 58% |
| mRNA-1273 | 62 | 31% |
| AD26.COV2.S | 20 | 10% |
| mRNA (type unknown) | 3 | 2% |